iPneucia® is the first  pneumococcal polysaccharide conjugate vaccine to utilize both CRM197 (a non-toxic diphtheria toxin mutant), and tetanus toxoid (TT) as carriers in China. Unlike other pneumococcal conjugate vaccines available in China, iPneucia® adopts a dual-carrier conjugate technology. This dual-carrier conjugation technology not only reduces reactogenicity associated with single-carrier dependency, but also minimizes interference when co-administered with other childhood vaccines. Notably, the vaccine exhibits enhanced immunogenicity  against four key serotypes (19F, 19A, 7F, and 3), which are responsible for the heaviest disease burden of pneumococcal infections among children in China.

iPneucia® was officially approved by China’s National Medical Products Administration in June 2025 for immunization of children aged 6 weeks to 5 years (<72 months). As an innovative vaccine, iPneucia® employs covalent conjugation between polysaccharide antigens and carrier proteins, converting T-cell-independent polysaccharide antigens into T cell-dependent antigens. This modification induces high-level specific antibodies in infants and young children under 2 years old and facilitates the generation of memory B cells for long-term immune memory .

In manufacturing, CanSinoBIO has implemented a safer production process featuring animal component-free fermentation media and phenol-free purification technology, thereby eliminating  risks associated with animal-derived materials and toxic residues while preserving vaccine immunogenicity. .